Get the latest market trends in your inbox
Stay on top of the latest market trends and economic insights with the Axios Markets newsletter. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul
Tampa-St. Petersburg news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg
Purdue Pharma headquarters in Stamford, Connecticut. Photo: Drew Angerer/Getty Images
The Sackler family, owners of Purdue Pharma, withdrew $10.7 billion from the company over the last dozen years, placing the money in trusts and overseas holding companies, according to an audit commissioned by Purdue and filed in bankruptcy court yesterday.
Why it matters: The revelation may reignite the debate over how much the Sacklers should be required to pay to resolve the thousands of lawsuits pending against Purdue for its role in the opioid epidemic, the New York Times reports. The family has offered to pay at least $3 billion in cash as part of a settlement, but some states have argued that the Sacklers should have to pay more.
Go deeper: New court documents show former Purdue Pharma chief's role in marketing OxyContin